Metraipolis › archive › dc_39ae8568eacc

Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational… — Europe PMC PMID:41431468

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41431468
DOI
10.1136/bmjmed-2025-001934
License (as archived)
solo-consultazione
Archived
2026-11-07T14:40:11.543Z
SHA-256 of the archived text
4c053d6ea91b19bd7a34e58dfae438da3dff32105e064f3acd84b4759c42f075
Stable URL of this page
https://metraipolis.com/documento/dc_39ae8568eacc

How to cite

Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational… — Europe PMC PMID:41431468 — Europe PMC (en), https://europepmc.org/article/MED/41431468 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39ae8568eacc (Metraipolis archive dc_39ae8568eacc, sha256 4c053d6ea91b19bd7a34e58dfae438da3dff32105e064f3acd84b4759c42f075)
BibTeX
@misc{dc39ae8568eacc,
  title = {Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational… — Europe PMC PMID:41431468},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41431468},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39ae8568eacc; sha256 4c053d6ea91b19bd7a34e58dfae438da3dff32105e064f3acd84b4759c42f075},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41431468. Agents can read the archived copy with the MCP tool read_document.